Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Milton Hobbs

Internal Medicine Oxford, MS Medical Doctor

NPI 1801902309 CMS profile 172363

551 Azalea Dr, Oxford, MS 38655

Open in the dashboard

General payments

$7,669

560 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Milton Hobbs of Oxford, MS is reported in the CMS Open Payments database as having received $7,669 across 560 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $61 4
2024 General $68 5
2023 General $155 10
2022 General $1,440 99
2021 General $2,368 167
2020 General $1,596 109
2019 General $1,981 166

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Milton Hobbs
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Milton Hobbs were reported at $61. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Milton Hobbs Internal Medicine median Middle half National median
2019 $1,981 $159 $48–$570 $163
2020 $1,596 $119 $33–$402 $114
2021 $2,368 $135 $37–$521 $132
2022 $1,440 $141 $42–$496 $149
2023 $155 $149 $45–$519 $160
2024 $68 $154 $47–$537 $164
2025 $61 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $917 65 payments
  2. Novo Nordisk Inc $824 68 payments
  3. AstraZeneca Pharmaceuticals LP $726 46 payments
  4. AbbVie, Inc. $713 60 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $506 32 payments
  6. Pfizer Inc. $422 36 payments
  7. Novartis Pharmaceuticals Corporation $381 27 payments
  8. Amgen Inc. $372 30 payments
  9. Merck Sharp & Dohme Corporation $348 25 payments
  10. Lilly USA, LLC $322 33 payments
  11. Other $2,139 138 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,565 558 payments
  2. Education $104 2 payments
Products named General payments · program years 2019–2025
  1. XARELTO $911 64 payments
  2. Ozempic $623 48 payments
  3. FARXIGA $554 35 payments
  4. RYBELSUS $481 34 payments
  5. JARDIANCE $471 30 payments
  6. INVOKANA $321 27 payments
  7. STEGLATRO $301 21 payments
  8. JANUVIA $301 21 payments
  9. ELIQUIS $276 26 payments
  10. STEGLUJAN $253 16 payments
  11. Other $6,171 490 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

560 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record